An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression

We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study, ISRCTN4...

Descripción completa

Detalles Bibliográficos
Autores principales: Obrișcă, Bogdan, Vornicu, Alexandra, Mocanu, Valentin, Dimofte, George, Andronesi, Andreea, Bobeică, Raluca, Jurubiță, Roxana, Sorohan, Bogdan, Caceaune, Nicu, Ismail, Gener
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656480/
https://www.ncbi.nlm.nih.gov/pubmed/37978255
http://dx.doi.org/10.1038/s41598-023-47393-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656480/
https://www.ncbi.nlm.nih.gov/pubmed/37978255
http://dx.doi.org/10.1038/s41598-023-47393-1

Ejemplares similares